Study of ASN51 in Adults With Early Alzheimer's Disease
Status:
TERMINATED
Trial end date:
2024-11-08
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety, tolerability, and effect on biomarkers of disease pathophysiology and pathology, pharmacokinetics (PK), and preliminary effects on measures of clinical efficacy of multiple doses of ASN51 in adult participants with early Alzheimer's disease (AD).